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Thyroid carcinoma is the most frequent endocrine cancer accounting for 5–10% of thy-
roid nodules. Papillary histotype (PTC) is the most prevalent form accounting for 80%
of all thyroid carcinoma. Although much is known about its epidemiology, pathogenesis,
clinical, and biological behavior, the only documented risk factor for PTC is the ionizing
radiation exposure. Rearrangements of the Rearranged during Transfection (RET ) proto-
oncogene are found in PTC and have been shown to play a pathogenic role. The ﬁrst RET
rearrangement, named RET /PTC, was discovered in 1987. This rearrangement constitu-
tively activates the transcription of the RET tyrosine-kinase domain in follicular cell, thus
triggering the signaling along the MAPK pathway and an uncontrolled proliferation. Up to
now, 13 different types of RET /PTC rearrangements have been reported but the two most
common are RET /PTC1 and RET /PTC3. Ionizing radiations are responsible for the gener-
ation of RET /PTC rearrangements, as supported by in vitro studies and by the evidence
that RET /PTC, and particularly RET /PTC3, are highly prevalent in radiation induced PTC.
However, many thyroid tumors without any history of radiation exposure harbor similar RET
rearrangements.The overall prevalence ofRET /PTC rearrangements varies from 20 to 70%
of PTCs and they are more frequent in childhood than in adulthood thyroid cancer. Con-
troversial data have been reported on the relationship between RET /PTC rearrangements
and the PTC prognosis. RET /PTC3 is usually associated with a more aggressive phenotype
and in particular with a greater tumor size, the solid variant, and a more advanced stage at
diagnosis which are all poor prognostic factors. In contrast, RET /PTC1 rearrangement does
not correlate with any clinical–pathological characteristics of PTC. Moreover, the RET pro-
tein and mRNA expression level did not show any correlation with the outcome of patients
with PTC and no correlation between RET /PTC rearrangements and the expression level
of the thyroid differentiation genes was observed. Recently, a diagnostic role of RET /PTC
rearrangements has been proposed. It can be searched for in the mRNA extracted from
cytological sample especially in case with indeterminate cytology. However, both the fact
that it can be present in a not negligible percentage of benign cases and the technical chal-
lenge in extracting mRNA from cytological material makes this procedure not applicable at
routine level, at least for the moment.
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INTRODUCTION
Thyroid nodules are a very common clinical ﬁnding; the preva-
lence of palpable nodules ranges from 4 to 7% in general popula-
tion (Mazzaferri, 1992; Gharib, 2004). Although only less than 5%
of palpable nodules are malignant lesions, thyroid cancers are the
most frequent endocrinemalignancy accounting for about 5–10%
of thyroid nodules (Braverman andUtiger, 2005). Epidemiological
studies in USA and in Europe demonstrated a relevant increased
incidence of thyroid cancer and, in particular, thyroid cancer rate
of incidence has been the highest among all human tumors dur-
ing the last decades (Farahati et al., 2004; Davies andWelch, 2006;
Kent et al., 2007; Enewold et al., 2009).
About 95% of malignant lesions are derived from thyroid
follicular cells and are distinguished into well differentiated,
either papillary (PTC) or follicular (FTC) histotype, and anaplas-
tic thyroid carcinoma (ATC; Cardis et al., 2006). As shown in
Figure 1, PTC is the most prevalent form accounting for about
80% of cases, while FTC represent only 15%. PTC and, to a
lesser extent, FTC have a good prognosis if adequately treated
(Elisei et al., 2010). Very rare (5%), but also very aggressive
and almost invariably lethal, is ATC. Another relatively small
percentage of thyroid carcinomas (7.5–10%; Schlumberger and
Pacini, 1999) are derived from parafollicular C cells and are
called medullary thyroid carcinoma (MTC; De Lellis et al., 2003;
Nikiforov, 2009).
In the last 25 years, many studies have been conducted to iden-
tify the genetic alterations related to the pathogenesis of these
tumors. Several oncogenes have been analyzed for mutations and
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FIGURE 1 |The prevalence of different histotypes among all thyroid
tumors: a clear higher prevalence of papillary thyroid cancer (about
80%) is usually reported in all series.
Table 1 | Different prevalences of different oncogenes reported to be
involved in thyroid carcinogenesis.
Oncogene Mean prevalence (%)*
BRAF 48
RET/PTC 20
APC 15
SMAD4 14
CTNNB1 12
IDH1 10
NTRK1 10
CDKN2A 9
EGFR 8
NRAS 4
HRAS 2
KRAS 2
PIK3CA 2
*Data derived from: http://www.sanger.ac.uk/genetics/CGP/cosmic/
some of them have been found to be strictly correlated with a
speciﬁc thyroid carcinoma histotype (Table 1).
In this review we will focus on PTC and in particular on the
relationship between the presence of RET /PTC rearrangements,
that have been deﬁned to be speciﬁc for PTC development and
the clinical and pathological features of PTC. The putative role of
RET /PTC rearrangements in the diagnosis and in the prediction
of prognosis will be discussed.
PAPILLARY THYROID CANCER
The annual incidence of thyroid cancer per 105 individuals ranges
from 1.2 to 2.6 in men and from 2.0 to 3.8 in women and tumor
mortality is very low (Franceschi et al., 1993). Thyroid cancer is
two to four times more frequent in females than in males. It is
rare in children below 16 years of age while in adults the incidence
increases with age and the median age at diagnosis is between 45
and 50 years.Differences in the incidence of thyroid cancer accord-
ing to ethnic origin have been also reported. These differencesmay
be due to environmental factors and dietary habits (Spitz et al.,
1988).
Although the etiology of PTC is not well understood, there are
some risk factors which are known to put an individual at higher
risk of developing the disease. Radiation exposure signiﬁcantly
increases the risk for thyroid malignancies, particularly PTC. This
ﬁnding was observed in children exposed to radiation after the
nuclear bombings in Hiroshima and Nagasaki during the Sec-
ond World War (Nagataki et al., 1994). Additional evidence was
gathered after atomic bombs were tested in the Marshall Islands
(Cronkite et al., 1995), after the accident at the Chernobyl nuclear
power plant (Williams, 2002; Nikiforov, 2006), and in patients
who received low-dose radiation therapy for benign disorders of
the head, neck, and thorax (Duffy and Fitzgerald, 1950; Winship
and Rosvoll, 1970).
Among other risk factors female gender play an important role
in fact it has been shown (Ron et al., 1987) that the sex ratio
approaches 1 before puberty and after menopause while during
the fertile woman age it is between two and four times higher than
in the correspondent men age period. A heavier body weight have
been shown also to increase the risk of thyroid cancer (Kitahara
et al., 2011).
An important role is also played by the iodine exposure. Areas
with low iodine intake usually show higher prevalence of FTC
than area with sufﬁcient iodine intake where, conversely, the PTC
histotype is more represented (Belﬁore et al., 1987). Furthermore
the high prevalence of thyroid cancer in regions where the iodine
intake is high suggests that iodine intake may play role in thyroid
tumorigenesis (Vejbjerg et al., 2007; Guan et al., 2009) as well as
other factors not related to iodine like volcanic activity (Pellegriti
et al., 2009).
RET/PTC REARRANGEMENTS
The RET proto-oncogene is located on chromosome 10q11.2 and
encodes for a transmembrane tyrosine-kinase receptor involved
in the control of cell differentiation and proliferation. Four dif-
ferent ligands have been reported up to now: glial derived neu-
rotrophic (GDN) factors, Neurturin (NRTN), Artimin (ARTN),
and Persepin (PSPN), respectively (Arighi et al., 2005). All these
ligands induce RET activation through the binding to speciﬁc
coreceptors. The RET gene is expressed in tissues deriving from
the neural crest including thyroid C cells and adrenal medulla but
it is not expressed in normal thyroid follicular cells (Santoro et al.,
1990).
In 1987 the ﬁrst ﬁnding of a new oncogene activated in human
PTC was reported (Fusco et al., 1987). Interestingly, the tumoral
tissue where the oncogene was ﬁrstly described was derived from
an irradiated PTC. After 3 years, this oncogene was molecularly
cloned: it was a chimeric gene generated by the fusion of the
RET tyrosine-kinase domain (Wirtschafter et al., 1997) with the
5′ terminal region of a new gene denominated CCD6 (formerly
calledH4; Figure 2; Grieco et al., 1990). This oncogene was named
RET /PTC.
After the ﬁrst identiﬁcation, several types of RET /PTC
rearrangements have been described (Greco et al., 2009; Table 2).
At the present 13 different types of RET /PTC rearrangements have
been reported and all of them are the result of the fusion of the
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RET tyrosine-kinase (TK) domain with different genes, which are
characterized by the presence of nucleotide sequences coding for
proteins with an extremely high probability of forming coiled-coil
domains, thus allowing constitutive dimerization of the RET -TK
domain. This constitutive dimerization determines an uncon-
trolled proliferation of the follicular cells harboring the RET /PTC
rearrangement and the development of malignancy. The presence
of RET /PTC rearrangement in microcarcinoma strongly support
the hypothesis of a driving role of this oncogene in the tumoral
transformation (Viglietto et al., 1995).
So far, RET /PTC rearrangements have been identiﬁed almost
exclusively in thyroid lesions, and in particular in PTC (San-
toro et al., 1993; Tallini and Asa, 2001; Nikiforov, 2002). To our
knowledge, the only other human tumor harboring RET /PTC
rearrangements is primary peritoneal carcinoma (Flavin et al.,
2009). However these rearrangements are supposed to be
FIGURE 2 | Schematic representation of RET /PTC1 rearrangement: a
centromeric inversion of chromosome 10 (A) generates a chimeric
gene through the fusion of the RET tyrosine-kinase domain with the
5′terminal region of a new gene denominated CCD6, formerly
called H4 (B).
Table 2 | Different types of RET/PTC rearrangements in thyroid tumors.
Oncogene Donor gene Chromosomal location
RET/PTC1 CCD6 (formerly H4) 10q21
RET/PTC2 PRKAR1A 17q23
RET/PTC3 NCO4 (formerly Ele 1) 10q11.2
RET/PTC4 NCO4 (formerly Ele 1) 10q11.2
RET/PTC5 Golgas 14q
RET/PTC6 TRIM24 7q32–34
RET/PTC7 TRIM33 1p13
RET/PTC8 KTN1 14q22.1
RET/PTC9 RFG9 18q21–22
ELKS–RET ELKS 12p13.3
PCM1–RET PCM1 8p21–22
RFP–RET TRIM27 6p21
HOOK3–RET HOOK3 8p11.21
“passenger” mutations reﬂecting RET instability in tumor sub-
clones more than true pathogenetic events. RET /PTC rearrange-
ments more frequently found in PTC are RET /PTC1, given by the
fusion with the CCDC6 (formerly H4) gene andRET /PTC3, given
by the fusion with the NCOA4 (formerly ELE1) gene (Santoro
et al., 1994).
The reported RET /PTC prevalence in thyroid tumors varies
greatly in different series (Zou et al., 1994; Lam et al., 1998; Mayr
et al., 1998; Chua et al., 2000; Cinti et al., 2000; Fenton et al.,
2000; Sheils et al., 2000; Puxeddu et al., 2003; Rhoden et al., 2004,
2006; Table 3). This difference can be attributed to ethnical and
geographic variations as well as to the different sensitivities of
detectionmethods (Zhu et al., 2006). It has been carefully demon-
strated that the method used has an important effect on the efﬁ-
cacy of RET /PTC rearrangement determination and thus on the
reported prevalence (Marotta et al., 2011). Tumor heterogeneity is
another factor that can affect the evaluation of RET /PTC preva-
lence. The distribution of RET /PTC rearrangement within the
same tumor may be heterogeneous, varying from the involvement
of most neoplastic cells (i.e., clonal RET /PTC) to the presence of
Table 3 | Prevalence of RET/PTC rearrangements in sporadic and
irradiated PTC.
Reference Post-Chernobyl n (%) Spontaneous n (%)
Guerra et al. (2011)** nd 36%
Hieber et al. (2011) 16/22 (72) nd
Hamatani et al. (2008) 11/50 (22)* nd
Rhoden et al. (2006) nd 25/34 (73)
Zhu et al. (2006) nd 26/75 (34)
Unger et al. (2006) 10/13 (77)˚ nd
9/32 (28)+
Di Cristofaro et al. (2005) 11/17 (65) 9/21 (43)
Rhoden et al. (2004) nd 18/25 (72)
Puxeddu et al. (2003) nd 13/48 (27)
Elisei et al. (2001) 19/25 (76) 11/47 (23)
Cinti et al. (2000) nd 13/69 (19)
Sheils et al. (2000) nd 12/50 (24)
Fenton et al. (2000) nd 15/33 (45)
Chua et al. (2000) nd 44/62 (71)
Thomas et al. (1999) 37/67 (55) nd
Smida et al. (1999) 25/51 (49) nd
Mayr et al. (1998) nd 8/99 (8)
Tallini et al. (1998) nd 81/201 (40)
Lam et al. (1998) nd 17/40 (43)
Sugg et al. (1999) nd 51/86 (59)
Nikiforov et al. (1997) 33/38 (87) 12/17 (70)
Klugbauer et al. (1995) 9/15 (60) nd
Fugazzola et al. (1995) 4/6 (66) nd
Zou et al. (1994) nd 1/40 (2.5)
Ishizaka et al. (1991) nd 1/11 (9)
*Atomic bomb survivors.
+Long latency period.
˚Short latency period.
**Data obtained on cytological samples.
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a small fraction of tumor cells (i.e., non-clonal RET /PTC) in the
sample (Unger et al., 2004; Zhu et al., 2006).
Clonal RET /PTC rearrangements occur in about 20% of PTC
and are speciﬁc for this tumor (Nikiforov, 2002, 2011; Zhu et al.,
2006). Non-clonalRET /PTC rearrangements have been found not
only in PTC but also in 10–45% of thyroid adenomas and other
non-neoplastic thyroid lesions (Ishizaka et al., 1991; Wirtschafter
et al., 1997; Sheils et al., 2000; Elisei et al., 2001; Chiappetta et al.,
2002; Sapio et al., 2011) andHashimoto’s thyroiditis (Rhoden et al.,
2006).
As shown in Table 3, RET /PTC rearrangements are more fre-
quently found in thyroid cancers following radiation exposure
(50–80%; Fugazzola et al., 1995; Nikiforov et al., 1997; Thomas
et al., 1999; Di Cristofaro et al., 2005; Unger et al., 2006; Hamatani
et al., 2008; Hieber et al., 2011). In particular RET /PTC3 has been
found to be more frequent than RET /PTC1 in post-Chernobyl
radiation exposed thyroid cancer especially in those with a short
latency period (Williams, 2008). RET /PTC rearrangements have
been also found to be more prevalent in children than in adults
both in irradiated and non-irradiated PTC (Nikiforov et al., 1997;
Elisei et al., 2001).
Over the time, the proportion of post-Chernobyl thyroid
tumors with a RET /PTC rearrangement has declined, and in
the RET /PTC-positive tumors the percentage of those with
RET /PTC1 has increased while the proportion of those with
RET /PTC3 has in parallel decreased (Unger et al., 2006). The
hypothesis to explain this variation is that with the increase of
latency period the effect of radiation is becoming less signiﬁcant
and most recently developed PTC around Chernobyl are more
similar to non-irradiated cases. This hypothesis is at least in part
supported by the evidence that also the histological features are
changing according to the latency period (Williams, 2008).
The high prevalence of RET /PTC rearrangements found in
post-Chernobyl thyroid tumors and in atomic bomb survivors
exposed to high-dose radiation (Hamatani et al., 2008) strongly
supports a direct role of radiation exposure in RET /PTC genera-
tion (Fugazzola et al., 1995; Klugbauer et al., 1995; Bounacer et al.,
1997; Nikiforov et al., 1997). RET /PTC rearrangements were also
found after high-dose radiation to human undifferentiated thy-
roid carcinoma cells (Ito et al., 1993) and to fetal human thyroid
tissue transplanted into SCIDmice (Mizuno et al., 2000). The gen-
eration of RET /PTC rearrangements has been also demonstrated
in normal thyroid cultured cells after in vitro exposure to radia-
tion (Gandhi et al., 2010a,b). Furthermore, the strong relationship
between ionizing radiation exposure and RET /PTC rearrange-
ments have been shown by aCOMET assay that demonstrated that
RET oncogene is very susceptible to ionizing radiation (Volpato
et al., 2008). Moreover, the spatial contiguity of RET andH4 genes
within the chromatinmay provide a structural basis for generation
of RET /PTC1 rearrangement by allowing a single radiation track
to produce a double-strand break in each gene (Nikiforova et al.,
2000; Gandhi et al., 2006, 2010a).
Over the last fewdecades, signiﬁcant progress has been achieved
in the understanding of the biological mechanisms of radia-
tion carcinogenesis. It has been shown that damage to cellular
DNA is responsible for mutagenesis and carcinogenesis and that
double-strand breaks is the most important event for the direct
generation of gene translocations and rearrangements. In particu-
lar there are several in vitro evidences demonstrating that thyroid
cells exposed to X-Ray develop RET /PTC rearrangements (Ito
et al., 1993; Goodhead, 1994; Ward, 1995; Mizuno et al., 2000;
Caudill et al., 2005). Other than ionizing radiations, other puta-
tive carcinogens, like caffeine, ethanol, hypoxia, and others, are
able to induce DNA double-strand breaks and generate RET /PTC
rearrangements (Gandhi et al., 2010a,b). Recently, a direct rela-
tionship between ionizing radiation exposure, intracellular hydro-
gen peroxidase (H2O2) generation, double-strand induction, and
RET /PTC1 rearrangements development was also demonstrated
(Ameziane-El-Hassani et al., 2010). After this observation, it can
be hypothesize that other agents able to initiate biological produc-
tion of superoxidase anions and H2O2 (Narayanan et al., 1997)
can induce RET /PTC rearrangements.
RET /PTC REARRANGEMENTS AND CLINICO-PATHOLOGICAL
FEATURES OF PTC
A correlation with a more aggressive phenotype and a more
advanced stage has been reported for RET /PTC rearrangements,
especially RET /PTC3 (Nikiforov et al., 1997; Powell et al., 1998).
In particular, in post-Chernobyl childhood thyroid cancer the
RET /PTC3 rearrangement was more frequently associated with
the solid variant of PTC which is considered a more aggressive
variant and the most prevalent among these irradiated tumors.
As matter of fact, with the increase of the latency period both the
solid variant and the RET/PTC rearrangements prevalence have
declined suggesting a strong relationship between radiation expo-
sure, solid variant, RET /PTC3 rearrangements, and a more rapid
development of the tumor as indicated by the short latency period
(Williams, 2008).
In a previous study on sporadic PTC we also demonstrated a
positive correlationbetween the presence of RET /PTC3 rearrange-
ment, but not of RET /PTC1, with a bigger size of the tumor and
a more advanced stage at diagnosis. However, in the same study
the levels of expression of thyroid differentiation genes (i.e., thy-
rotropin stimulating hormone receptor, thyroglobulin, sodium-
iodide symporter etc.) was shown to be not signiﬁcantly different
in PTC with or without RET /PTC rearrangements, thus suggest-
ing that these genetic alterations should not play a major role in
the de-differentiation process (Romei et al., 2008).
Controversial data have been also reported about the correla-
tion of the presence of RET /PTC rearrangements and clinical and
epidemiological features of patients with PTC. Although there is
a general agreement that RET /PTC rearrangements, particularly
RET /PTC1, are more frequent in young patients, also in non-
irradiated cases (Elisei et al., 2001) there are other studies that
did not show any correlation between RET /PTC rearrangements
and age, sex, tumor size, staging, number of neoplastic foci, and
histological subtype (Puxeddu et al., 2004).
So far no consensus concerning the clinical prognostic value
of the presence of a RET /PTC rearrangement, either RET /PTC3
or RET /PTC1, has been reached. Some evidences exists sug-
gesting that PTC with RET /PTC1 rearrangement are associated
with a more favorable behavior (Saad et al., 2004) while those
harboring RET /PTC3 rearrangement may be more prone to de-
differentiation and a more aggressive behavior (Sugg et al., 1999;
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Mochizuki et al., 2010). Initial reports on this speciﬁc issue claimed
a role inmetastatic spread (Jhiang andMazzaferri, 1994; Sugg et al.,
1999) and more recently, it has been suggested that RET /PTC-
positive cases show higher rates of local extension and lymph node
involvement than RET/PTC negative cases (Adeniran et al., 2006).
At variance, several other studies were unable to ﬁnd any relation-
ship between RET/PTC rearrangements and classical prognostic
factors (Tallini et al., 1998; Musholt et al., 2000; Basolo et al., 2001;
Romei et al., 2008).
In our experience, RET /PTC rearrangements do not seem to
be correlated with any clinical and pathological feature of aggres-
siveness either by studying the expression of the RET /PTC protein
by immunohistochemistry (Basolo et al., 2001) or by studying the
mRNA expression of the RET /PTC rearrangements by real time
RT-PCR (Romei et al., 2008).
DIAGNOSTIC ROLE OF RET /PTC REARRANGEMENTS
Fine needle aspiration cytology (FNAC) is the ﬁrst choice method
to distinguish between benign and malignant thyroid nodules
(Pacini et al., 2006; Baloch and LiVolsi, 2008; Cooper et al., 2009).
However, about 30% of FNAC yields uncertain results because of
inadequate sampling (i.e., only few cells or great blood contami-
nation) or because cytological features do not clearly indicate the
nature of the lesion (i.e., follicular neoplasia; Gharib et al., 1984;
Mazzaferri, 1993). Whenever a follicular neoplasia is diagnosed,
surgical treatment, and histological examination are required to
differentiate the malignant from the benign nature of the nod-
ule. Since only 20–30% of these nodules turn out to be malignant
(Rago et al., 2007),about 80%of patientswith a follicular neoplasia
undergo an unnecessary thyroidectomy.
The rapidly expanding knowledge of molecular genetics of thy-
roid cancer has started to translate into clinical practice, offering
signiﬁcant improvement in accuracy of the preoperative diagnosis
of thyroid cancer. Several studies have been already published on
the possibility to improve the diagnostic power of FNAC by look-
ing for thyroid cancer speciﬁc oncogenic alterations (Nikiforova
and Nikiforov, 2009). Most studies have explored the diagnos-
tic role of BRAF mutation (Jin et al., 2006; Xing et al., 2009;
Adeniran et al., 2011; Marchetti et al., 2012). In a large prospec-
tive study recently published, the detection of BRAF mutations in
FNA showed a very high positive predictive value (PPV). How-
ever, the biggest diagnostic impact can be achieved only by testing
FNA samples for a panel of mutations (i.e., BRAF, RET /PTC,
RAS,TRK ) rather than for a single mutation (Cantara et al., 2010;
Guerra et al., 2011). Indeed, RET /PTC detection can improve the
preoperative diagnosis of thyroid nodules, particularly in sam-
ples that are indeterminate by cytology or have an insufﬁcient
amount of cells for cytologic evaluation (Cheung et al., 2001; Sal-
vatore et al., 2004; Pizzolanti et al., 2007). Nevertheless the PPV
of the detection of RET /PTC rearrangements is not as high as
the detection of BRAF mutations because a low, but not negligi-
ble, percentage of nodules positive for RET/PTC rearrangements
on FNA which turned out to be benign at histology (Cantara
et al., 2010; Guerra et al., 2011). This is not unexpected since,
have previously said, there are several reports showing that 5%
of benign thyroid nodules and several cases of Hashimoto’s thy-
roiditis are positive for RET /PTC rearrangements. Last but not
least, the search for RET /PTC rearrangements requires the mRNA
extraction form the cytological smears that is a much more chal-
lenging techniques than the extraction of DNA that is required for
the search of BRAF. As matter of fact, at the present the search for
RET /PTC rearrangements in cytologically indeterminate thyroid
nodule is still not considered a diagnostic routine tool.
CONCLUSION
In the last years important achievements have been reached in the
understanding of the molecular basis of PTC. Although different
oncogenes have been found to be altered in PTC,BRAF mutations,
and RET /PTC rearrangements are the most frequently involved.
A lot has been discovered between the relationship of RET /PTC
rearrangements and PTC clinical, pathological, and epidemio-
logical features. Although present also in non-irradiated cases,
RET /PTC rearrangements are related to radiation exposure and
are more frequent in patients with radio induced PTC. Among
all RET /PTC rearrangements, RET /PTC1, and RET /PTC3 are in
general the most frequent. RET /PTC3 is much more prevalent
in irradiated PTC especially in those with solid variants. Both of
them are more prevalent in children than in adults. Despite all
these observations there are not yet clear data showing a deﬁnitive
prognostic role of neither RET /PTC1 or RET /PTC3. The presence
of aRET /PTC rearrangement in the RNAs extracted from cytolog-
ical material aspirated from a thyroid nodule is strongly predictive
of malignancy but some cases of benign nodules can also result to
be positive.
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